Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness

Fig. 1

Higher expression of SHP2 indicates poor survival and Osimertinib resistance in LUAD patients. A High SHP2-expressing LAUD patients suffered poor OS (71.27 months vs. 112.67 months, p = 0.00062) and PFS (21.3 months vs. 37 months, p = 0.00019) than low SHP2-expressing patients. B The IC50 of PC9 and PC9GR cells to Osimertinib treated for 72 h were 0.0004861 and 8.272, respectively. C LUAD cancer cells express high level SHP2 protein than BEAS-2B pulmonary epithelial cells, and PC9GR cells harboring higher SHP2 than PC9 cells. More interestingly, SHP2 was enriched in Osimertinib treated PC9GR and PC9 cells compared with corresponding control cells. D Higher SHP2 protein expressed in the tumor of Osimertinib treated tumor than that of DMSO group. Each experiment was repeated 3 times

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us